Advertisement
Clinical Therapeutics
Advanced searchSave search
Editorial| Volume 18, ISSUE 1, P126, January 1996

Pharmaceutical economics & health policy

Editorial comment
DOI:https://doi.org/10.1016/S0149-2918(96)80185-8
Pharmaceutical economics & health policy
Previous ArticleThe efficacy, tolerability, and safety of 1200 mg/d of oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with osteoarthritis of the knee
Next ArticleOsteoporosis: the need for comprehensive treatment guidelines
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(96)80185-8

      Copyright

      © 1996 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX